Literature DB >> 28578735

DEVELOPMENTS IN VALUE FRAMEWORKS TO INFORM THE ALLOCATION OF HEALTHCARE RESOURCES.

Wija Oortwijn1, Laura Sampietro-Colom2, Fay Habens3.   

Abstract

BACKGROUND: In recent years, there has been a surge in the development of frameworks to assess the value of different types of health technologies to inform healthcare resource allocation. The reasons for, and the potential of, these value frameworks were discussed during the 2017 Health Technology Assessment International (HTAi) Policy Forum Meeting.
METHODS: This study reflects the discussion, drawing on presentations from invited experts and Policy Forum members, as well as a background paper.
RESULTS: The reasons given for a proliferation of value frameworks included: rising healthcare costs; more complex health technology; perceived disconnect between price and value in some cases; changes in societal values; the need for inclusion of additional considerations, such as ethical issues; and greater empowerment of clinicians and patients in defining and using value frameworks. Many Policy Forum participants recommended learning from existing frameworks. Furthermore, there was a desire to agree on the core components of value frameworks, defining the additional value elements as necessary and considering how they might be measured and used in practice. Furthermore, adherence to the principles of transparency, predictability, broad stakeholder involvement, and accountability were widely supported, along with being forward looking, explicit, and consistent across decisions.
CONCLUSIONS: Value frameworks continue to evolve with significant implications for global incentives for innovation and access to health technologies. There is a role for the HTA community to address some of the key areas discussed during the meeting, such as defining the core components for assessing the value of a health technology.

Entities:  

Keywords:  Decision making; Health technology assessment; Value framework

Mesh:

Year:  2017        PMID: 28578735     DOI: 10.1017/S0266462317000502

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  5 in total

1.  Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries-A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses.

Authors:  Ivett Jakab; Bertalan Németh; Baher Elezbawy; Melis Almula Karadayı; Hakan Tozan; Sabahattin Aydın; Jie Shen; Zoltán Kaló
Journal:  Front Pharmacol       Date:  2020-08-14       Impact factor: 5.810

2.  Balanced assessment systems revisited.

Authors:  Dávid Dankó; Márk Péter Molnár
Journal:  J Mark Access Health Policy       Date:  2017-07-26

Review 3.  Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures.

Authors:  Thomas Morel; Stefan J Cano
Journal:  Orphanet J Rare Dis       Date:  2017-11-02       Impact factor: 4.123

4.  Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile.

Authors:  Ting Wang; Neil McAuslane; Wim G Goettsch; Hubert G M Leufkens; Marie L De Bruin
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

5.  Evaluating facts and facting evaluations: On the fact-value relationship in HTA.

Authors:  Bjørn Hofmann; Ken Bond; Lars Sandman
Journal:  J Eval Clin Pract       Date:  2018-04-03       Impact factor: 2.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.